Gasparini G, Pozza F, Dittadi R, Meli S, Cazzavillan S, Bevilacqua P
St. Bortolo Regional Hospital, USSL 8, Vicenza, Italy.
J Cancer Res Clin Oncol. 1992;118(7):557-63. doi: 10.1007/BF01225273.
Immunocytochemical assay (ICA) of the progesterone receptor (PgR) was performed on 152 patients with stage I-II breast cancer. We employed the rat monoclonal antibody KD-68 and a peroxidase/antiperoxidase displaying system. The results obtained by ICA (Pg(RICA)) were compared with those by the biochemical dextran-coated charcoal assay (PgRDCC). Comparing the two methods we found an overall agreement (accuracy) of 77.5%, a PgR(ICA) sensitivity of 83.5% and a specificity of 73%. Both methods were significantly associated with oestrogen receptor expression, detected by DCC (P less than 0.001 for PgRDCC and P = 0.0014 for PgR(ICA)). No significant association was found between PgR(ICA) or PgRDCC and the other clinicopathological features analysed. After a median follow-up of 36 months, the overall survival probability was 91% in PgRDCC-positive versus 81.5% in PgRDCC-negative patients (log-rank test, chi 2 = 0.91) compared to 87.5% in PgR(ICA)-positive versus 82% in PgR(ICA)-negative ones (log-rank test, chi 2 = 0.93). Disease-free survival probability was 74.5% in both PgRDCC-positive and PgRDCC-negative patients (log-rank test, chi 2 = 0.02) compared to 78% in PgR(ICA)-positive versus 71.5% in PgR(ICA)-negative cases (log-rank test, chi 2 = 0.37). The present study demonstrates that ICA is a reliable method to detect PgR, correlating well with the DCC assay. Moreover, the ICA assay seems to provide clinical information complementary to the biochemical method. The definition of its prognostic value in operable breast cancer needs additional studies, particularly in node-negative patients.
对152例I-II期乳腺癌患者进行了孕激素受体（PgR）的免疫细胞化学检测（ICA）。我们使用了大鼠单克隆抗体KD-68和过氧化物酶/抗过氧化物酶显示系统。将ICA获得的结果（Pg(RICA)）与生化葡聚糖包被活性炭检测法（PgRDCC）的结果进行比较。比较这两种方法，我们发现总体一致性（准确性）为77.5%，PgR(ICA)的敏感性为83.5%，特异性为73%。两种方法均与通过DCC检测的雌激素受体表达显著相关（PgRDCC的P<0.001，PgR(ICA)的P = 0.0014）。未发现PgR(ICA)或PgRDCC与所分析的其他临床病理特征之间存在显著关联。中位随访36个月后，PgRDCC阳性患者的总生存概率为91%，而PgRDCC阴性患者为81.5%（对数秩检验，χ2 = 0.91），相比之下，PgR(ICA)阳性患者为87.5%，PgR(ICA)阴性患者为82%（对数秩检验，χ2 = 0.93）。PgRDCC阳性和PgRDCC阴性患者的无病生存概率均为74.5%（对数秩检验，χ2 = 0.02），相比之下，PgR(ICA)阳性患者为78%，PgR(ICA)阴性患者为71.5%（对数秩检验，χ2 = 0.37）。本研究表明，ICA是检测PgR的可靠方法，与DCC检测法相关性良好。此外，ICA检测似乎能提供与生化方法互补的临床信息。其在可手术乳腺癌中的预后价值的定义需要更多研究，尤其是在淋巴结阴性患者中。
